Labcorp Holdings INC

Labcorp Holdings Inc. announced its third quarter 2026 financial results will be released on October 28, 2026, with a webcast to follow.

Labcorp Holdings Inc. reaffirms its 2026-2029 financial outlook while expressing concerns over potential steep annual payment cuts from new CMS clinical laboratory fee schedule rates.

Labcorp Holdings Inc. hosted its 2026 Investor Day, reaffirming full-year 2026 guidance and presenting a long-term financial outlook through 2029 with projected compound annual revenue growth of 5% to 8%.

Labcorp Holdings Inc. announced its executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.

Labcorp Holdings Inc. announced it will host an Investor Day on September 10, 2026, where leadership will discuss strategy, capital deployment, and financial outlook.

Labcorp Holdings Inc. announced a key executive departure and internal appointment, effective September 2026, impacting leadership of its laboratory services.

Labcorp Holdings Inc. announced its first-quarter 2026 financial results, reporting a 5.8% increase in total revenues to $3,537.6 million, driven by organic growth and acquisitions.

Labcorp Holdings Inc. reported a significant increase in Q3 2025 revenues and net earnings, driven by robust organic growth and strategic acquisitions across its Diagnostics and Biopharma segments.

Labcorp Holdings Inc. announced a significant increase in revenues and net earnings for the second quarter and first half of 2025, fueled by strong organic growth and strategic acquisitions across its core laboratory services.

Labcorp's Q1 2025 revenue increased by 5.3% year-over-year, driven by acquisitions and organic growth, despite unfavorable foreign currency translation.

Labcorp Holdings Inc. announced a 7.4% increase in revenue for the third quarter of 2024, driven by acquisitions and growth in its base business, while also detailing its financial position and ongoing legal matters.

Labcorp Holdings Inc. announced a 6.2% increase in revenue for the second quarter of 2024, driven by strong growth in its base business and strategic acquisitions.

Labcorp Holdings Inc. reported a 7.2% revenue increase to $13.95 billion in 2025, driven by organic growth and strategic acquisitions, while navigating healthcare cost pressures and investing in specialty testing and AI.

Labcorp's 2024 annual report reveals a 7% revenue increase, fueled by strong performance in its core diagnostics and biopharma laboratory services.

Labcorp's 2023 annual report details a 2.5% revenue increase, driven by strategic acquisitions and base business growth, alongside a focus on innovation and strategic partnerships.

Akinbolade Oyegunwa, EVP, CIO & CTO of Labcorp Holdings Inc., received 750 shares of common stock on September 1, 2026.

Jonathan C Meltzer, EVP, COO of Labcorp Holdings Inc., received 900 shares of common stock on September 1, 2026.

Bryan T Vaughn, EVP and President, Diagnostics of Labcorp Holdings Inc., received 1,500 shares of common stock on September 1, 2026.

Brian J Caveney, EVP, Pres of BLS, CMO & CSO of Labcorp Holdings Inc., received 3,000 shares of common stock on September 1, 2026.

Kerrii B Anderson, a Director of Labcorp Holdings Inc., sold 3,000 shares of common stock on August 17, 2026 for $318.02 per share.

Adam H Schechter, President & CEO and a Director of Labcorp Holdings Inc., sold 4,669 shares of common stock on August 11, 2026 for $320.37 per share.

Labcorp Holdings Inc. announced its 2026 Annual Meeting of Shareholders, scheduled for May 21, 2026, and provided a comprehensive overview of its 2025 performance and strategic priorities.

Labcorp Holdings Inc. announces its 2025 Annual Meeting of Shareholders, detailing proposals for director elections, executive compensation, incentive plans, and auditor ratification.

Labcorp announces its 2025 Annual Shareholder Meeting and reflects on a year of strong financial performance and strategic advancements.

Laboratory Corporation of America Holdings (Labcorp) will hold its annual shareholder meeting on May 14, 2024, to vote on key proposals including the election of directors, executive compensation, and ratification of the company's auditor.

Labcorp's 2024 proxy statement outlines the company's transformational year in 2023, marked by the successful spin-off of Fortrea and continued focus on growth opportunities.

Vanguard Capital Management disclosed a beneficial ownership of 7.52% in Labcorp Holdings Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Labcorp Holdings Inc. following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in Labcorp Holdings Inc. as of March 31, 2025.